Media Advisories

Updates for media on the latest products, offerings and developments across our business.

View all
Filter Results
Filter Results
General (512) Financials (100) Partnerships (72) Ad hoc (40) New Products (34) Acquisitions (25) New Technologies (10)
Corporate (398) Specialized Modalities (118) Integrated Biologics (98) Capsules & Health Ingredients (63) Advanced Synthesis (28)
2025 (13) 2024 (24) 2023 (25) 2022 (39) 2021 (65) 2020 (84) 2019 (100) 2018 (91) 2017 (79) 2016 (75) 2015 (57) 2014 (59)
English (609) Deutsch (98) French (4)
   Loading...
Showing 1‐20 of 500
12 Sep 2025
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez as Chief Quality Officer
Jason Berndt will join Lonza on 1 October 2025 as new Head of Group Operations, Executive Vice President and member of the Executive Committee (EC) Maria Soler Nunez, currently...
23 Jul 2025
​​Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook​
​​Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook​
23 Jul 2025
​​Lonza erzielt starkes Ergebnis im ersten Halbjahr 2025 und erhöht Umsatz- und Margenprognose für das CDMO-Geschäft im Gesamtjahr 2025​
​​Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook​
27 May 2025
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Structure
The One Lonza organizational structure became effective on 1 April 2025 and comprises three CDMO Business Platforms: Integrated Biologics, Advanced Synthesis and Specialized...
15 May 2025
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
Andreas Bohrer has served as Lonza’s Group General Counsel and Company Secretary since 2015  As of 1 July 2025, Andreas joins Lonza’s Executive Committee as Chief Legal &...
09 May 2025
Lonza Announces Results of the 2025 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Jean-Marc Huët was re-elected as Chair of the Board of Directors  Juan Andres, Eric Drapé and David Meline have been elected as Members of the Board of Directors Shareholders...
09 May 2025
Lonza gibt Ergebnisse der Generalversammlung 2025 bekannt – Alle Anträge des Verwaltungsrates wurden genehmigt
Jean-Marc Huët wurde als Präsident des Verwaltungsrates wiedergewählt Juan Andres, Eric Drapé und David Meline wurden als Mitglieder des Vewaltungsrates gewählt Die...
09 May 2025
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in Line with Expectations for Full-Year 2025
Strong CDMO1 performance in Q1 2025, in line with expectations for FY 2025 Robust commercial demand in CDMO business with high utilization in early-stage business, Bioscience...
03 Apr 2025
Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports
Annual General Meeting will take place on 9 May 2025 at the Congress Center in Basel, Switzerland Jean-Marc Huët proposed for re-election as Chair of the Board of Directors...
01 Apr 2025
Lonza Implements its Simplified and Streamlined Operating Model
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy Previous divisional structure is now replaced with three newly...
01 Apr 2025
Lonza Completes its Share Buyback Program
Basel, Switzerland, 1 April 2025 – Lonza today announced the successful completion of its share buyback program of up to CHF 2 billion which was launched on 3 April 2023. Through...
29 Jan 2025
Lonza Delivers Solid 2024 Performance with CER Sales in Line with Prior Year and 29.0% CORE EBITDA Margin
In 2024, Lonza delivered sales of CHF 6.6 billion in line with prior year (-0.2% CER1) CORE EBITDA of CHF 1.9 billion at a margin of 29.0% The CDMO2  business delivered a...
29 Jan 2025
Lonza erzielt für 2024 ein solides Ergebnis mit konstantem Umsatz und 29.0% Kern-EBITDA-Marge
Im Jahr 2024 erzielte Lonza einen Umsatz von CHF 6.6 Milliarden (-0.2% kWk1  gegenüber dem Vorjahr) Kern-EBITDA von CHF 1.9 Milliarden ergab eine Marge von 29.0% Das...
12 Dec 2024
​​Lonza Investor Update 2024​ Outlines Strategy, New Organizational Structure and Guidance
Lonza has provided an overview of its new “One Lonza” strategy and new organizational structure
12 Nov 2024
Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites
The expansion of bioconjugation capabilities will provide additional manufacturing capacity for launch and commercial supply, addressing growing market demand 2,000m2 of...
24 Oct 2024
Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024
Outlook 2024 confirmed: Flat year-on-year sales in CER and a CORE EBITDA margin of high 20s  Strong commercial and operational performance across the CDMO business in...
22 Oct 2024
Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC The...
03 Oct 2024
Lonza Nominates David Meline as Independent Board Member
David Meline brings extensive governance, financial and industry experience to Lonza’s Board of Directors Olivier Verscheure will not stand for re-election at the 2025 Annual...
01 Oct 2024
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche
The Vacaville site is one of the largest biologics manufacturing facilities in the world Acquisition extends Lonza’s US Biologics footprint with a significant presence on the...
24 Sep 2024
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel)
Lonza to manufacture CASGEVY®, the world’s first CRISPR/Cas9 gene-edited cell therapy, for global commercial supply CASGEVY® will be manufactured at Lonza’s Geleen (NL) cell...